Clinical trials
Advanced Hepatocellular Carcinoma clinical trials
Below are recruiting advanced hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 250 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04601428RecruitingEarly Phase 1
Liver artery treatment for certain liver cancer patients
This early-phase study tests a treatment delivered through the liver’s artery for people with intermediate or limited advanced liver cancer who can’t have surgery. It aims to control the cancer after prior targeted liver treatments didn’t work or the cancer grew again.
Tainan, North Dist.Ages 18 years+ - NCT04770207RecruitingPhase 2
Injecting a cancer drug mixture directly into tumors
This Phase 2 study tests a treatment where drug-loaded tiny beads are injected into a solid tumor, using more than one medicine. It may help people with advanced solid cancers by delivering the drugs right at the tumor site.
Guangzhou, GuangdongAges 18–99 - NCT05096715RecruitingPhase 1
Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
Boston, MassachusettsAges 18 years+ - NCT05443087Recruiting
Checking blood levels of targeted drugs for digestive cancers
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
AmiensAges 18 years+ - NCT05486572Recruiting
Ultrasound or MRI to help prevent liver cancer deaths
This study compares ultrasound scans versus MRI scans to see which one better helps prevent deaths from liver cancer in people with cirrhosis. You may be assigned to one of the two imaging tests and follow-up visits to track whether liver cancer develops or is caught early.
Birmingham, AlabamaAges 18–75 - NCT05652920RecruitingPhase 1/Phase 2
CAR T-cell therapy for liver cancer that has GPC3
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–70 - NCT05917431RecruitingPhase 2
Radiation plus immunotherapy and targeted pills for liver cancer
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05937295RecruitingPhase 1
Peptide vaccine plus immunotherapy for a specific cancer gene fusion
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
Tübingen, Baden-WürtembergAges 18 years+ - NCT06007846RecruitingPhase 2/Phase 3
Memantine for advanced liver cancer and cirrhosis
This trial tests if memantine, a medication typically used for memory problems, can help people with advanced liver cancer and cirrhosis. It is for those who cannot have standard aggressive treatments.
Fairfax, VirginiaAges 18 years+ - NCT06031285RecruitingPhase 2
Perioperative immunotherapy plus TACE-HAIC for liver cancer with portal vein tumor thrombus
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
Guangzhou, GuangdongAges 18–75 - NCT06294548RecruitingPhase 1/Phase 2
Valemetostat plus atezolizumab and bevacizumab for advanced liver cancer
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
Birmingham, AlabamaAges 18 years+ - NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06518434RecruitingPhase 2
Cannabis oil for advanced liver cancer study
This study tests if cannabis oil can help people with advanced liver cancer that cannot be treated with standard therapies. It is a small pilot study to see if the oil is safe and may improve symptoms or quality of life.
GroningenAges 18 years+ - NCT06805552Recruiting
Sarcopenia and targeted therapy in liver cancer
This study looks at muscle loss in people with liver cancer who are receiving targeted therapy (TKIs). It aims to understand how muscle health affects treatment outcomes. You may qualify if you have intermediate or advanced liver cancer or earlier stage that hasn't responded to prior treatments.
BolognaAges 18 years+ - NCT06819566RecruitingPhase 2
Preventing bleeding from enlarged veins in the esophagus
This study tests whether tying off high-risk veins in the esophagus before starting a common liver cancer treatment can prevent bleeding. It is for people with liver cancer that has spread but who have never had cancer treatment before.
Seoul, Song-paAges 19–80 - NCT06999707RecruitingPhase 2
Radiation plus immunotherapy for advanced liver cancer
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06999694RecruitingPhase 2
Proton radiation with immunotherapy for liver cancer
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT07365930Recruiting
TIPS treatment support for liver cancer patients on Atezo + Bev
This study looks at whether adding TIPS (a procedure to reduce fluid buildup) to standard immunotherapy (atezolizumab and bevacizumab) helps people with advanced liver cancer who also have cirrhosis. It's for patients whose cancer cannot be removed by surgery or has progressed after other local treatments.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT07639138RecruitingPhase 2
Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT06061328Enrolling by invitation
Project OASIS: Finding better ways to improve care for cirrhosis
This trial tests different approaches to help doctors and hospitals improve care for veterans with cirrhosis. If you have cirrhosis and are not post-transplant or currently being treated for liver cancer, you might be able to join and help find the best strategies.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05441475Enrolling by invitationPhase 2
Trial for advanced liver cancer using ABSK-011 plus atezolizumab
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
Hubei, Shanghai MunicipalityAges 18 years+ - NCT07105748RecruitingPhase 2
HAIC plus Camrelizumab and Rivoceranib for advanced mixed liver-bile duct cancer
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced hepatocellular carcinoma?
- Yes. Clin2 currently lists 250 recruiting advanced hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.